Clinical Cancer Research · 2017 · 13 citations · 37 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyTumor ProgressionCancer BiomarkersMalignant NeoplasmsMolecular Classification Of TumorsMolecular Tumor ProfilingPersonalized Cancer TherapyTumor ClassificationAnticancer ActivityFibroblast Growth Factor Receptor SignalingMesothelioma ScreeningPersonalized Cancer MedicinePersonalized Cancer TreatmentPersonalized Treatment PathwaysPersonalized Treatment RecommendationTumor Profiling
Abstract Purpose: Finding new treatment options for patients with malignant pleural mesothelioma is challenging due to the rarity and heterogeneity of this cancer type. The absence of druggable targets further complicates the development of new therapies. Current treatment options are therefore limited, and prognosis remains poor. Experimental Design: We performed drug screening on primary mesothelioma cultures to guide treatment decisions of corresponding patients that were progressive after first- or second-line treatment. Results: We observed a high concordance between in vitro results and clinical outcomes. We defined three subgroups responding differently to the anticancer drugs tested. In addition, gene expression profiling yielded distinct signatures that segregated the differently responding subgroups. These genes signatures involved various pathways, most prominently the fibroblast growth factor pathway. Conclusions: Our primary mesothelioma culture system has proved to be suitable to test novel drugs. Chemical profiling of primary mesothelioma cultures allows personalizing treatment for a group of patients with a rare tumor type where clinical trials are notoriously difficult. This personalized treatment strategy is expected to improve the poor prospects of patients with mesothelioma. Clin Cancer Res; 24(7); 1761–70. ©2017 AACR. See related commentary by John and Chia, p. 1513
37
Gene expression profiling predicts clinical outcome of breast cancer
Laura van ‘t Veer, Hongyue Dai, Marc J. van de Vijver et al. · Nature · 2002 · 9.6K citations · Full text
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Charity W. Law, Yunshun Chen, Wei Shi et al. · Genome biology · 2014 · 6.7K citations · Full text
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett, Elena J. Edelman, Sonja J. Heidorn et al. · Nature · 2012 · 2.6K citations · Full text
Medicine, Cancer Biology, Oncology +16